PALB2 germline pathogenic in EOC: rare (~1%); biologically HR-deficient. Niraparib NOVA n...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-PALB2-GERMLINE-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | PALB2 germline pathogenic |
| Disease | DIS-OVARIAN |
| ESCAT tier | IIA |
| Recommended combinations | niraparib maintenance, olaparib + bevacizumab (HRD-positive), rucaparib maintenance |
| Evidence summary | PALB2 germline pathogenic in EOC: rare (~1%); biologically HR-deficient. Niraparib NOVA non-gBRCA cohort and rucaparib ARIEL3 LOH-high included PALB2; olaparib + bev (PAOLA-1) in HRD-positive includes PALB2. ESCAT IIA / OncoKB Level 3A. |
Notes
Cascade testing mandatory. PALB2 carriers face breast and pancreatic risk in relatives.
Used By
No reverse references found in the YAML corpus.